Company Overview of Therapix Biosciences Ltd.
Therapix Biosciences Ltd., a biopharmaceutical company, identifies and develops specialty biopharmaceuticals. It develops LP-306, a novel pharmaceutical based on cannabinoids for pain management; and TRX-318, an oral monoclonal antibody for the treatment of auto-immune and inflammatory diseases. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is based in Tel Aviv, Israel.
5 Azrieli Center (Square Tower)
Tel Aviv, 6702501
Founded in 2004
972 3 616 7055
972 3 616 7056
Key Executives for Therapix Biosciences Ltd.
Therapix Biosciences Ltd. Key Developments
Similar Private Companies By Industry
|CARDIAPEX Ltd.||Middle East/Africa|
|VAYA Pharma Inc.||Middle East/Africa|
|Recogene Ltd.||Middle East/Africa|
|Fertility Labs Ltd.||Middle East/Africa|
Recent Private Companies Transactions
August 3, 2015
To contact Therapix Biosciences Ltd., please visit www.therapixbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.